Children  ||| S:0 E:9 ||| NNS
with  ||| S:9 E:14 ||| IN
chronic  ||| S:14 E:22 ||| JJ
kidney  ||| S:22 E:29 ||| NN
disease  ||| S:29 E:37 ||| NN
and  ||| S:37 E:41 ||| CC
hypertension ||| S:41 E:53 ||| NN
:  ||| S:53 E:55 ||| :
could  ||| S:55 E:61 ||| MD
hypertension  ||| S:61 E:74 ||| VB
footprints  ||| S:74 E:85 ||| RB
be  ||| S:85 E:88 ||| VB
early  ||| S:88 E:94 ||| JJ
biomarkers ||| S:94 E:104 ||| NN
?  ||| S:104 E:106 ||| .
Hypertension  ||| S:106 E:119 ||| NNP
( ||| S:119 E:120 ||| -LRB-
HT ||| S:120 E:122 ||| NNP
)  ||| S:122 E:124 ||| -RRB-
is  ||| S:124 E:127 ||| VBZ
one  ||| S:127 E:131 ||| CD
of  ||| S:131 E:134 ||| IN
the  ||| S:134 E:138 ||| DT
major  ||| S:138 E:144 ||| JJ
problems  ||| S:144 E:153 ||| NNS
in  ||| S:153 E:156 ||| IN
chronic  ||| S:156 E:164 ||| JJ
kidney  ||| S:164 E:171 ||| NN
disease  ||| S:171 E:179 ||| NN
( ||| S:179 E:180 ||| -LRB-
CKD ||| S:180 E:183 ||| NNP
) ||| S:183 E:184 ||| -RRB-
,  ||| S:184 E:186 ||| ,
not  ||| S:186 E:190 ||| RB
only  ||| S:190 E:195 ||| RB
for  ||| S:195 E:199 ||| IN
adults ||| S:199 E:205 ||| NNS
,  ||| S:205 E:207 ||| ,
but  ||| S:207 E:211 ||| CC
also  ||| S:211 E:216 ||| RB
for  ||| S:216 E:220 ||| IN
children ||| S:220 E:228 ||| NNS
.  ||| S:228 E:230 ||| .
It  ||| S:230 E:233 ||| PRP
is  ||| S:233 E:236 ||| VBZ
one  ||| S:236 E:240 ||| CD
of  ||| S:240 E:243 ||| IN
the  ||| S:243 E:247 ||| DT
main  ||| S:247 E:252 ||| JJ
factors  ||| S:252 E:260 ||| NNS
in  ||| S:260 E:263 ||| IN
the  ||| S:263 E:267 ||| DT
progression  ||| S:267 E:279 ||| NN
of  ||| S:279 E:282 ||| IN
CKD ||| S:282 E:285 ||| NNP
,  ||| S:285 E:287 ||| ,
increased  ||| S:287 E:297 ||| VBN
rate  ||| S:297 E:302 ||| NN
of  ||| S:302 E:305 ||| IN
cardiovascular  ||| S:305 E:320 ||| JJ
disease ||| S:320 E:327 ||| NN
,  ||| S:327 E:329 ||| ,
and  ||| S:329 E:333 ||| CC
impairment  ||| S:333 E:344 ||| NN
in  ||| S:344 E:347 ||| IN
quality  ||| S:347 E:355 ||| NN
of  ||| S:355 E:358 ||| IN
life ||| S:358 E:362 ||| NN
.  ||| S:362 E:364 ||| .
The  ||| S:364 E:368 ||| DT
most  ||| S:368 E:373 ||| RBS
important  ||| S:373 E:383 ||| JJ
devastating  ||| S:383 E:395 ||| JJ
effect  ||| S:395 E:402 ||| NN
of  ||| S:402 E:405 ||| IN
HT  ||| S:405 E:408 ||| NNP
is  ||| S:408 E:411 ||| VBZ
on  ||| S:411 E:414 ||| IN
the  ||| S:414 E:418 ||| DT
cardiovascular  ||| S:418 E:433 ||| JJ
system ||| S:433 E:439 ||| NN
.  ||| S:439 E:441 ||| .
It  ||| S:441 E:444 ||| PRP
may  ||| S:444 E:448 ||| MD
leave  ||| S:448 E:454 ||| VB
significant  ||| S:454 E:466 ||| JJ
footprints  ||| S:466 E:477 ||| NN
in  ||| S:477 E:480 ||| IN
developing  ||| S:480 E:491 ||| VBG
children  ||| S:491 E:500 ||| NNS
that  ||| S:500 E:505 ||| WDT
can  ||| S:505 E:509 ||| MD
be  ||| S:509 E:512 ||| VB
carried  ||| S:512 E:520 ||| VBN
over  ||| S:520 E:525 ||| RP
to  ||| S:525 E:528 ||| TO
adulthood ||| S:528 E:537 ||| VB
.  ||| S:537 E:539 ||| .
Existing  ||| S:539 E:548 ||| VBG
data  ||| S:548 E:553 ||| NNS
clearly  ||| S:553 E:561 ||| RB
show  ||| S:561 E:566 ||| VB
that  ||| S:566 E:571 ||| IN
in  ||| S:571 E:574 ||| IN
CKD  ||| S:574 E:578 ||| NNP
children  ||| S:578 E:587 ||| NNS
with  ||| S:587 E:592 ||| IN
proteinuria  ||| S:592 E:604 ||| VBG
the  ||| S:604 E:608 ||| DT
blood  ||| S:608 E:614 ||| NN
pressure  ||| S:614 E:623 ||| NN
goal  ||| S:623 E:628 ||| NN
should  ||| S:628 E:635 ||| MD
be  ||| S:635 E:638 ||| VB
50th  ||| S:638 E:643 ||| JJ
centile ||| S:643 E:650 ||| NN
,  ||| S:650 E:652 ||| ,
while  ||| S:652 E:658 ||| IN
it  ||| S:658 E:661 ||| PRP
is  ||| S:661 E:664 ||| VBZ
75th  ||| S:664 E:669 ||| JJ
centile  ||| S:669 E:677 ||| NN
in  ||| S:677 E:680 ||| IN
those  ||| S:680 E:686 ||| DT
without  ||| S:686 E:694 ||| IN
proteinuria ||| S:694 E:705 ||| NN
.  ||| S:705 E:707 ||| .
Renin-angiotensin  ||| S:707 E:725 ||| JJ
system  ||| S:725 E:732 ||| NN
inhibitors  ||| S:732 E:743 ||| NNS
are  ||| S:743 E:747 ||| VBP
considered  ||| S:747 E:758 ||| VBN
the  ||| S:758 E:762 ||| DT
first  ||| S:762 E:768 ||| JJ
choice  ||| S:768 E:775 ||| NN
pharmacological  ||| S:775 E:791 ||| NN
option  ||| S:791 E:798 ||| NN
in  ||| S:798 E:801 ||| IN
hypertensive  ||| S:801 E:814 ||| JJ
CKD  ||| S:814 E:818 ||| NNP
stage  ||| S:818 E:824 ||| NN
2  ||| S:824 E:826 ||| CD
to  ||| S:826 E:829 ||| TO
4  ||| S:829 E:831 ||| CD
patients ||| S:831 E:839 ||| NNS
.  ||| S:839 E:841 ||| .
However ||| S:841 E:848 ||| RB
,  ||| S:848 E:850 ||| ,
in  ||| S:850 E:853 ||| IN
clinical  ||| S:853 E:862 ||| JJ
practice ||| S:862 E:870 ||| NN
,  ||| S:870 E:872 ||| ,
pediatric  ||| S:872 E:882 ||| JJ
nephrologists  ||| S:882 E:896 ||| NN
may  ||| S:896 E:900 ||| MD
experience  ||| S:900 E:911 ||| VB
significant  ||| S:911 E:923 ||| JJ
problems  ||| S:923 E:932 ||| NNS
in  ||| S:932 E:935 ||| IN
treatment  ||| S:935 E:945 ||| NN
and  ||| S:945 E:949 ||| CC
follow-up  ||| S:949 E:959 ||| JJ
of  ||| S:959 E:962 ||| IN
these  ||| S:962 E:968 ||| DT
patients ||| S:968 E:976 ||| NNS
,  ||| S:976 E:978 ||| ,
especially  ||| S:978 E:989 ||| RB
in  ||| S:989 E:992 ||| IN
compliance ||| S:992 E:1002 ||| NN
.  ||| S:1002 E:1004 ||| .
Due  ||| S:1004 E:1008 ||| JJ
to  ||| S:1008 E:1011 ||| TO
multiple  ||| S:1011 E:1020 ||| JJ
drug  ||| S:1020 E:1025 ||| NN
use ||| S:1025 E:1028 ||| NN
,  ||| S:1028 E:1030 ||| ,
physician-patient  ||| S:1030 E:1048 ||| JJ
and  ||| S:1048 E:1052 ||| CC
family  ||| S:1052 E:1059 ||| NN
cooperation  ||| S:1059 E:1071 ||| NN
would  ||| S:1071 E:1077 ||| MD
be  ||| S:1077 E:1080 ||| VB
essential  ||| S:1080 E:1090 ||| JJ
to  ||| S:1090 E:1093 ||| TO
improve  ||| S:1093 E:1101 ||| VB
the  ||| S:1101 E:1105 ||| DT
compliance ||| S:1105 E:1115 ||| NN
.  ||| S:1115 E:1117 ||| .
Remembering  ||| S:1117 E:1129 ||| VBG
the  ||| S:1129 E:1133 ||| DT
fact  ||| S:1133 E:1138 ||| NN
that  ||| S:1138 E:1143 ||| IN
prevention  ||| S:1143 E:1154 ||| NN
is  ||| S:1154 E:1157 ||| VBZ
always  ||| S:1157 E:1164 ||| RB
cheaper  ||| S:1164 E:1172 ||| JJR
than  ||| S:1172 E:1177 ||| IN
treatment ||| S:1177 E:1186 ||| NN
,  ||| S:1186 E:1188 ||| ,
we  ||| S:1188 E:1191 ||| PRP
need  ||| S:1191 E:1196 ||| VBP
early  ||| S:1196 E:1202 ||| JJ
detection  ||| S:1202 E:1212 ||| NN
of  ||| S:1212 E:1215 ||| IN
CKD  ||| S:1215 E:1219 ||| NNP
and  ||| S:1219 E:1223 ||| CC
its  ||| S:1223 E:1227 ||| PRP$
devastating  ||| S:1227 E:1239 ||| JJ
complications ||| S:1239 E:1252 ||| NNS
,  ||| S:1252 E:1254 ||| ,
like  ||| S:1254 E:1259 ||| IN
HT ||| S:1259 E:1261 ||| NNP
.  ||| S:1261 E:1263 ||| .
Therefore ||| S:1263 E:1272 ||| RB
,  ||| S:1272 E:1274 ||| ,
active  ||| S:1274 E:1281 ||| JJ
screening  ||| S:1281 E:1291 ||| NN
programs  ||| S:1291 E:1300 ||| NNS
should  ||| S:1300 E:1307 ||| MD
be  ||| S:1307 E:1310 ||| VB
encouraged  ||| S:1310 E:1321 ||| VBN
in  ||| S:1321 E:1324 ||| IN
children ||| S:1324 E:1332 ||| NNS
,  ||| S:1332 E:1334 ||| ,
as  ||| S:1334 E:1337 ||| RB
well  ||| S:1337 E:1342 ||| RB
as  ||| S:1342 E:1345 ||| IN
trying  ||| S:1345 E:1352 ||| VBG
to  ||| S:1352 E:1355 ||| TO
find  ||| S:1355 E:1360 ||| VB
new  ||| S:1360 E:1364 ||| JJ
biomarkers ||| S:1364 E:1374 ||| NN
,  ||| S:1374 E:1376 ||| ,
inspired  ||| S:1376 E:1385 ||| VBN
from  ||| S:1385 E:1390 ||| IN
the  ||| S:1390 E:1394 ||| DT
footprints  ||| S:1394 E:1405 ||| NN
of  ||| S:1405 E:1408 ||| IN
HT ||| S:1408 E:1410 ||| NNP
.  ||| S:1410 E:1412 ||| .
Although  ||| S:1412 E:1421 ||| IN
the  ||| S:1421 E:1425 ||| DT
researches  ||| S:1425 E:1436 ||| NN
on  ||| S:1436 E:1439 ||| IN
new  ||| S:1439 E:1443 ||| JJ
urinary  ||| S:1443 E:1451 ||| JJ
biomarkers  ||| S:1451 E:1462 ||| NN
for  ||| S:1462 E:1466 ||| IN
early  ||| S:1466 E:1472 ||| JJ
detection  ||| S:1472 E:1482 ||| NN
of  ||| S:1482 E:1485 ||| IN
CKD  ||| S:1485 E:1489 ||| NNP
and  ||| S:1489 E:1493 ||| CC
HT  ||| S:1493 E:1496 ||| NNP
are  ||| S:1496 E:1500 ||| VBP
promising ||| S:1500 E:1509 ||| VBG
,  ||| S:1509 E:1511 ||| ,
more  ||| S:1511 E:1516 ||| JJR
studies  ||| S:1516 E:1524 ||| NNS
are  ||| S:1524 E:1528 ||| VBP
needed  ||| S:1528 E:1535 ||| VBN
in  ||| S:1535 E:1538 ||| IN
this  ||| S:1538 E:1543 ||| DT
area ||| S:1543 E:1547 ||| NN
.  ||| S:1547 E:1549 ||| .
This  ||| S:1549 E:1554 ||| DT
review  ||| S:1554 E:1561 ||| NN
aims  ||| S:1561 E:1566 ||| VBZ
to  ||| S:1566 E:1569 ||| TO
give  ||| S:1569 E:1574 ||| VB
an  ||| S:1574 E:1577 ||| DT
overview  ||| S:1577 E:1586 ||| NN
of  ||| S:1586 E:1589 ||| IN
HT  ||| S:1589 E:1592 ||| NNP
in  ||| S:1592 E:1595 ||| IN
CKD  ||| S:1595 E:1599 ||| NNP
children ||| S:1599 E:1607 ||| NNS
,  ||| S:1607 E:1609 ||| ,
mainly  ||| S:1609 E:1616 ||| RB
focusing  ||| S:1616 E:1625 ||| VBG
on  ||| S:1625 E:1628 ||| IN
importance  ||| S:1628 E:1639 ||| NN
of  ||| S:1639 E:1642 ||| IN
HT ||| S:1642 E:1644 ||| NNP
,  ||| S:1644 E:1646 ||| ,
basic  ||| S:1646 E:1652 ||| JJ
principles  ||| S:1652 E:1663 ||| NNS
of  ||| S:1663 E:1666 ||| IN
treatment ||| S:1666 E:1675 ||| NN
,  ||| S:1675 E:1677 ||| ,
problems  ||| S:1677 E:1686 ||| NNS
in  ||| S:1686 E:1689 ||| IN
follow  ||| S:1689 E:1696 ||| VB
up ||| S:1696 E:1698 ||| RP
,  ||| S:1698 E:1700 ||| ,
and  ||| S:1700 E:1704 ||| CC
possible  ||| S:1704 E:1713 ||| JJ
markers  ||| S:1713 E:1721 ||| NN
for  ||| S:1721 E:1725 ||| IN
early  ||| S:1725 E:1731 ||| JJ
detection  ||| S:1731 E:1741 ||| NN
of  ||| S:1741 E:1744 ||| IN
CKD  ||| S:1744 E:1748 ||| NNP
and  ||| S:1748 E:1752 ||| CC
HT ||| S:1752 E:1754 ||| NNP
.  ||| S:1754 E:1756 ||| .
